Antibodies have always been the fundamental part of any research as their role in medical diagnostics and treatment is evolving with every passing day. As a result, the development of conventional and fragment antibodies constantly encounter a lot of challenges for the enhancement in volume and quality. To solve this ever-growing need, scientists have been developing a plethora of formats and alternative production platforms. Here in this blog, a critical comparison and assessment of distinct options is done to aid researchers in demonstrating recombinant antibodies in their choice.
The diagnostic market is estimated around $10bn/year, whereas, the global therapeutic antibody market stands around a staggering $50bn/year, and the research market accounts for $3bn/year. The average annual growth rate for the entire antibody applications in the past two decades has been over 5% and the recombinant sector has seen drastic growth.
These statistics prove that biological innovations are aimed in these areas; to improve the antibody production process with regards to absolute yields, structural stability, and functional reliability of the outcome. The ever-growing interest towards the recombinant antibodies is seen for several reasons. This includes:
- Conducting simple and straight engineering with the help of basic molecular biology methods
- Creating binders of variable formats and blended to different effectors and tags
- Developing the final shapes with low costs for microbial factories.
- Maintaining stable material clonality, which happens to be the important requirement for better results.
This trend will grow in the future as predicted by scientists since there has been a growing demand for structural features of some prominent antibody-based reagents. These are Immunotoxins, Antibody Drug Conjugates (ADCs), Bispecific Antibodies, and Bispecific T cell Engager. There’s no doubt that the huge structural variability of the immune-reagents requires effective reagents that are easy to use. Simultaneously, this implies the obligation of creating personalised expression and purification methods made for construct specificities to ensure that the yields are sufficient. Since this context is extremely complex, there’s a need to compare advantages and drawbacks of alternative platforms. The research talks about all the trends, and focuses on the evaluation of the level of feasibility achieved by different methodologies.
Instead of having a complete list of all the recent publications related to this filed, this research was done to examine the development of the latest and fastest growing strategies. These were explained with some examples, and compared with existing alternatives. All the solutions that may demonstrate intriguing opportunities are given the needed space. These solutions can investigate some important aspects of the production optimisation. However, the data we have isn’t sufficient and does not allow for a final judgment,
The extract from this study is that there is a defined process of progressive diversification related to the antibody expression platforms. A lot of efforts have been made to yield the application-adapted immune-reagents directly, rather than the generic basic antibodies that require further in vitro modification steps prior to becoming stable. (Marco, 2015)
For more information about DNA extraction, RNA extraction, and high quality laboratory kits, get in touch with MBP inc today. We have all the best lab equipment for DNA testing and all other biological research methodologies.
Marco, A. d. (2015). Recombinant antibody production evolves into multiple options aimed at yielding reagents suitable for application-specific needs. Microbial Cell Factories.